iniparib
Iniparib was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 and possibly other enzymes through covalent modification, but its effects against PARP were later disproven. It underwent clinical trials for treatment of some types of breast cancer, but was discontinued after disappointing phase III clinical trials. — Wikipedia
Clinical trial activity
21 trials · 7 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2006 (NCT00298675)
Timeline
Indications
Mechanism of action
- PARP 1, 2 and 3INHIBITOR
PARP 1, 2 and 3 inhibitor
- Unspecified targetOTHER
Reactive nitro radical
Initially proposed to be a PARP inhibitor but was found not to inhibit PARP at relevant concentrations. Iniparib is a prodrug that yields and nitro radical ion that can bind to cysteine residues in RedOx enzymes.
Chemistry & pharmacology
SMILES
NC(=O)c1ccc(I)c([N+](=O)[O-])c1- Mol. weight
- 292.03 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIniparib ↗
- ChEMBLCHEMBL1170047 ↗
Also known as
- 4-iodo-3-nitrobenzamide
- bsi201
- bsi 201
- bsi-201
- bsi-201
- bsi-201
- iniparib
- iniparib
- iniparib
- iniparib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01551680 | Phase 1 | Sep 1, 2012 | University of Montpellier |
| NCT01593228 | Phase 3 | May 1, 2012 | Sanofi |
| NCT01455532 | Phase 1 | Nov 1, 2011 | Sanofi |
| NCT01204125 | Phase 2 | Sep 1, 2010 | Sanofi, SOLTI Breast Cancer Research Group |
| NCT01213381 | Phase 1 | Sep 1, 2010 | Sanofi |
| NCT01161836 | Phase 1 | Jul 1, 2010 | Sanofi |
| NCT01173497 | Phase 2 | Jul 1, 2010 | Sanofi, University of North Carolina at Chapel Hill |
| NCT01130259 | N/A | May 24, 2010 | Sanofi |
| NCT01086254 | Phase 2 | May 1, 2010 | Sanofi |
| NCT01082549 | Phase 3 | Mar 1, 2010 | Sanofi |
| NCT01045304 | Phase 2 | Feb 1, 2010 | Sanofi |
| NCT01033292 | Phase 2 | Dec 1, 2009 | Sanofi |
| NCT01033123 | Phase 2 | Dec 1, 2009 | Sanofi |
| NCT00938652 | Phase 3 | Jul 1, 2009 | Sanofi |
| NCT00813956 | Phase 2 | Dec 1, 2008 | Breast Cancer Research Foundation, Sanofi |
| NCT00687765 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2008 | Sanofi |
| NCT00677079 | Phase 2 | Jun 1, 2008 | Sanofi |
| NCT00687687 | Phase 2 | May 1, 2008 | Gynecologic Oncology Group, Sanofi |
| NCT00540358 | Phase 2 | Oct 1, 2007 | BiPar Sciences, Sanofi |
| NCT00422682 | Phase 1 | Jan 1, 2007 | Sanofi |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 20 | 20 | 4 | 2006 |
| BiPar Sciences | For profit | 1 | 0 | 1 | 2007 |
| Breast Cancer Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2008 |
| SOLTI Breast Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Montpellier | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2010 |